Anixa Biosciences is trading 5.46% higher at $3.09 following its October 26 announcement of ovarian cancer CAR-T trial progress. The update is a plausible company-specific catalyst, but reporting does not explicitly confirm it caused the pre-market move.
- The company completed dosing the fifth cohort; its first patient had stable disease, with no dose-limiting toxicities reported to date.
- A sixth cohort is planned after a safety verification period.